Traynor Capital Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Traynor Capital Management’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,131	Closed	-$222K	–	194
2017 Q4	$222K	Sell	4,131 -176	-4%	-$9.63K	0.09%	150
2017 Q3	$244K	Sell	4,307 -39	-0.9%	-$2.28K	0.12%	131
2017 Q2	$268K	Sell	4,346 -295	-6%	-$16.8K	0.13%	129
2017 Q1	$264K	Buy	+4,641	New	+$229K	0.15%	118

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Traynor Capital Management's BIVV Position: Q1 2018 in Review

Traynor Capital Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 4,131 shares — an estimated $222K sold.

Traynor Capital Management first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $268K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Traynor Capital Management reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Traynor Capital Management sold 4,131 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $222K.
Traynor Capital Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Traynor Capital Management's Bioverativ Inc. Common Stock position peaked at $268K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Traynor Capital Management's 13F filing for Q1 2018, filed 1 May 2018.